

# Michael Henry Malim

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6080047/michael-henry-malim-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147  
papers

18,090  
citations

63  
h-index

134  
g-index

165  
ext. papers

20,666  
ext. citations

15.1  
avg, IF

6.71  
L-index

#	Paper	IF	Citations
147	Homebrew: an economical and sensitive glassmilk-based nucleic-acid extraction method for SARS-CoV-2 diagnostics.. <i>Cell Reports Methods</i> , <b>2022</b> , 100186		1
146	Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.. <i>MBio</i> , <b>2022</b> , e0379821	7.8	4
145	Homebrew: Protocol for glassmilk-based nucleic-acid extraction for SARS-CoV-2 diagnostics.. <i>STAR Protocols</i> , <b>2022</b> , 3, 101300	1.4	0
144	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.. <i>Cell Reports</i> , <b>2022</b> , 110757	10.6	0
143	Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 73	7	0
142	Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. <i>Lancet Rheumatology</i> , <b>2021</b> ,	14.2	12
141	Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients. <i>Blood</i> , <b>2021</b> , 138, 3920-3920	2.2	
140	TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009820	7.6	2
139	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , <b>2021</b> , 6, 1433-1442	26.6	32
138	Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer. <i>Cancer Cell</i> , <b>2021</b> , 39, 1445-1447	24.3	8
137	Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T <sub>H</sub> 1 cell response in allogeneic stem cell transplantation recipients. <i>Cancer Cell</i> , <b>2021</b> , 39, 1448-1449	24.3	5
136	Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation <b>2021</b> ,		15
135	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	46
134	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. <i>PLoS ONE</i> , <b>2021</b> , 16, e0249791	3.7	3
133	Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. <i>Nature</i> , <b>2021</b> , 594, 88-93	50.4	103
132	Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. <i>Lancet Oncology</i> , <b>2021</b> , 22, 765-778	21.7	240
131	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. <i>Leukemia</i> , <b>2021</b> , 35, 3573-3577	10.7	26

130	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 999-1006	4.5	24
129	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , <b>2021</b> , 54, 1276-1289.e6	32.3	60
128	Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections <b>2021</b> ,		5
127	HIV-1 Vpr Induces Widespread Transcriptomic Changes in CD4 T Cells Early Postinfection. <i>MBio</i> , <b>2021</b> , 12, e0136921	7.8	4
126	SARS-CoV-2 recruits a haem metabolite to evade antibody immunity <b>2021</b> ,		8
125	Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike <b>2021</b> ,		13
124	MX2-mediated innate immunity against HIV-1 is regulated by serine phosphorylation. <i>Nature Microbiology</i> , <b>2021</b> , 6, 1031-1042	26.6	2
123	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. <i>Clinical Microbiology and Infection</i> , <b>2021</b> ,	9.5	7
122	Minimal impact of ZAP on lentiviral vector production and transduction efficiency. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2021</b> , 23, 147-157	6.4	
121	Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. <i>Lancet Microbe, The</i> , <b>2021</b> , 2, e461-e471	22.2	31
120	The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e627-e637	14.2	47
119	Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation. <i>PLoS ONE</i> , <b>2021</b> , 16, e0256813	8.13	11
118	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. <i>Journal of Infection</i> , <b>2020</b> , 81, 931-936	18.9	32
117	Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. <i>Analyst, The</i> , <b>2020</b> , 145, 5638-5646	5	14
116	Translational Research in the Time of COVID-19-Dissolving Boundaries. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008898	8.98	1
115	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <i>Nature Microbiology</i> , <b>2020</b> , 5, 1598-1607	26.6	667
114	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008817	7.6	72
113	Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. <i>Nature Medicine</i> , <b>2020</b> , 26, 1701-1707	50.5	170

112	Immunoproteasome activation enables human TRIM5 $\alpha$ restriction of HIV-1. <i>Nature Microbiology</i> , <b>2019</b> , 4, 933-940	26.6	33
111	Kinetics of Early Innate Immune Activation during HIV-1 Infection of Humanized Mice. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	3
110	The GTPase Domain of MX2 Interacts with the HIV-1 Capsid, Enabling Its Short Isoform to Moderate Antiviral Restriction. <i>Cell Reports</i> , <b>2019</b> , 29, 1923-1933.e3	10.6	11
109	Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases. <i>Nucleic Acids Research</i> , <b>2019</b> , 47, 1178-1194	20.1	29
108	APOBEC restriction goes nuclear. <i>Nature Microbiology</i> , <b>2019</b> , 4, 6-7	26.6	2
107	Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing T cell biology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 1039-1044	11.5	83
106	Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G. <i>Nature Microbiology</i> , <b>2018</b> , 3, 220-233	26.6	55
105	The interferon-inducible isoform of NCOA7 inhibits endosome-mediated viral entry. <i>Nature Microbiology</i> , <b>2018</b> , 3, 1369-1376	26.6	33
104	Multiple components of the nuclear pore complex interact with the amino-terminus of MX2 to facilitate HIV-1 restriction. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1007408	7.6	28
103	Effects of Inner Nuclear Membrane Proteins SUN1/UNC-84A and SUN2/UNC-84B on the Early Steps of HIV-1 Infection. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	14
102	Lorenzo-Redondo et al. reply. <i>Nature</i> , <b>2017</b> , 551, E10	50.4	5
101	Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors. <i>Journal of Virology</i> , <b>2016</b> , 90, 7469-7480	6.6	23
100	Persistent HIV-1 replication maintains the tissue reservoir during therapy. <i>Nature</i> , <b>2016</b> , 530, 51-56	50.4	419
99	Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. <i>Nature Immunology</i> , <b>2016</b> , 17, 204-13	19.1	101
98	Oligomerization Requirements for MX2-Mediated Suppression of HIV-1 Infection. <i>Journal of Virology</i> , <b>2016</b> , 90, 22-32	6.6	28
97	A triple-arginine motif in the amino-terminal domain and oligomerization are required for HIV-1 inhibition by human MX2. <i>Journal of Virology</i> , <b>2015</b> , 89, 4676-80	6.6	46
96	Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1004609	7.6	64
95	HIV-1 and interferons: who's interfering with whom?. <i>Nature Reviews Microbiology</i> , <b>2015</b> , 13, 403-13	22.2	193

94	Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection. <i>Virology</i> , <b>2015</b> , 482, 72-8	3.6	12
93	HIV: Ringside views. <i>Nature</i> , <b>2014</b> , 505, 167-8	50.4	4
92	Nuclear import of SAMHD1 is mediated by a classical karyopherin $\beta$ dependent pathway and confers sensitivity to VpxMAC induced ubiquitination and proteasomal degradation. <i>Retrovirology</i> , <b>2014</b> , 11, 29	3.6	32
91	New insights into an X-traordinary viral protein. <i>Frontiers in Microbiology</i> , <b>2014</b> , 5, 126	5.7	19
90	Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor. <i>Journal of Virology</i> , <b>2014</b> , 88, 9017-26	6.6	61
89	Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. <i>PLoS Pathogens</i> , <b>2014</b> , 10, e1004281	7.6	65
88	Cooperativity among Rev-associated nuclear export signals regulates HIV-1 gene expression and is a determinant of virus species tropism. <i>Journal of Virology</i> , <b>2014</b> , 88, 14207-21	6.6	17
87	Evidence for IFN $\beta$ induced, SAMHD1-independent inhibitors of early HIV-1 infection. <i>Retrovirology</i> , <b>2013</b> , 10, 23	3.6	49
86	Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. <i>Nature</i> , <b>2013</b> , 502, 559-62	50.4	385
85	Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. <i>Journal of Virology</i> , <b>2013</b> , 87, 1508-17	6.6	83
84	Insight into the HIV-1 Vif SOCS-box-ElonginBC interaction. <i>Open Biology</i> , <b>2013</b> , 3, 130100	7	6
83	The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses. <i>Journal of General Virology</i> , <b>2012</b> , 93, 565-576	4.9	39
82	Endogenous MOV10 inhibits the retrotransposition of endogenous retroelements but not the replication of exogenous retroviruses. <i>Retrovirology</i> , <b>2012</b> , 9, 53	3.6	71
81	HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies. <i>Journal of Virology</i> , <b>2012</b> , 86, 11712-24	6.6	41
80	HIV Restriction Factors and Mechanisms of Evasion. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2012</b> , 2, a006940	5.4	333
79	AIDS/HIV. HIV interplay with SAMHD1. <i>Science</i> , <b>2012</b> , 335, 1313-4	33.3	16
78	How Representative Are Research Tissue Biobanks of the Local Populations? Experience of the Infectious Diseases Biobank at King's College, London, UK. <i>Biopreservation and Biobanking</i> , <b>2011</b> , 9, 287-288	2.1	3
77	Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. <i>Journal of Virology</i> , <b>2011</b> , 85, 13448-52	6.6	53

76	Evolution of a species-specific determinant within human CRM1 that regulates the post-transcriptional phases of HIV-1 replication. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002395	7.6	26
75	Rationalisation of the differences between APOBEC3G structures from crystallography and NMR studies by molecular dynamics simulations. <i>PLoS ONE</i> , <b>2010</b> , 5, e11515	3.7	16
74	SRp40 and SRp55 promote the translation of unspliced human immunodeficiency virus type 1 RNA. <i>Journal of Virology</i> , <b>2010</b> , 84, 6748-59	6.6	52
73	Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. <i>Journal of Virology</i> , <b>2010</b> , 84, 10402-5	6.6	90
72	Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. <i>Journal of Virology</i> , <b>2010</b> , 84, 9254-66	6.6	109
71	The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. <i>PLoS Pathogens</i> , <b>2010</b> , 6, e1000925	7.6	64
70	Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. <i>Journal of Virology</i> , <b>2009</b> , 83, 9474-85	6.6	252
69	Guidelines for naming nonprimate APOBEC3 genes and proteins. <i>Journal of Virology</i> , <b>2009</b> , 83, 494-7	6.6	182
68	RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. <i>PLoS Pathogens</i> , <b>2009</b> , 5, e1000330	7.6	134
67	Matrix mediates the functional link between human immunodeficiency virus type 1 RNA nuclear export elements and the assembly competency of Gag in murine cells. <i>Journal of Virology</i> , <b>2009</b> , 83, 8525-35	6.6	35
66	APOBEC proteins and intrinsic resistance to HIV-1 infection. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , <b>2009</b> , 364, 675-87	5.8	207
65	Unsung hero Robert C. Gallo. <i>Science</i> , <b>2009</b> , 323, 206-7	33.3	2
64	SnapShot: HIV-1 proteins. <i>Cell</i> , <b>2008</b> , 133, 742, 742.e1	56.2	33
63	HIV-1 accessory proteins--ensuring viral survival in a hostile environment. <i>Cell Host and Microbe</i> , <b>2008</b> , 3, 388-98	23.4	440
62	Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. <i>Journal of Virology</i> , <b>2008</b> , 82, 5636-42	6.6	66
61	APOBEC3G inhibits elongation of HIV-1 reverse transcripts. <i>PLoS Pathogens</i> , <b>2008</b> , 4, e1000231	7.6	247
60	Hypermutation of an ancient human retrovirus by APOBEC3G. <i>Journal of Virology</i> , <b>2008</b> , 82, 8762-70	6.6	76
59	Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. <i>Hepatology</i> , <b>2007</b> , 46, 682-9	11.2	68

58	APOBEC-mediated viral restriction: not simply editing?. <i>Trends in Biochemical Sciences</i> , <b>2007</b> , 32, 118-28	10.3	227
57	TRIM5 alpha cytoplasmic bodies are highly dynamic structures. <i>Molecular Biology of the Cell</i> , <b>2007</b> , 18, 2102-11	3.5	57
56	Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. <i>Journal of Virology</i> , <b>2007</b> , 81, 2165-78	6.6	222
55	APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 2587-95	5.4	252
54	Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. <i>Journal of Virology</i> , <b>2007</b> , 81, 3807-15	6.6	162
53	A plea for justice for jailed medical workers. <i>Science</i> , <b>2006</b> , 314, 924-5	33.3	3
52	Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. <i>Journal of Virology</i> , <b>2006</b> , 80, 8450-8	6.6	246
51	Natural resistance to HIV infection: The Vif-APOBEC interaction. <i>Comptes Rendus - Biologies</i> , <b>2006</b> , 329, 871-5	1.4	34
50	Retrovirus RNA trafficking: from chromatin to invasive genomes. <i>Traffic</i> , <b>2006</b> , 7, 1440-50	5.7	47
49	Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. <i>Current Biology</i> , <b>2005</b> , 15, 166-70	6.3	405
48	Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. <i>Virology</i> , <b>2005</b> , 334, 147-53	3.6	52
47	APOBEC-mediated interference with hepadnavirus production. <i>Hepatology</i> , <b>2005</b> , 42, 301-9	11.2	122
46	Further investigation of simian immunodeficiency virus Vif function in human cells. <i>Journal of Virology</i> , <b>2004</b> , 78, 12041-6	6.6	71
45	Retroviral mRNA nuclear export elements regulate protein function and virion assembly. <i>EMBO Journal</i> , <b>2004</b> , 23, 2632-40	13	116
44	Cytidine deamination of retroviral DNA by diverse APOBEC proteins. <i>Current Biology</i> , <b>2004</b> , 14, 1392-6	6.3	526
43	Long HIV type 1 reverse transcripts can accumulate stably within resting CD4+ T cells while short ones are degraded. <i>AIDS Research and Human Retroviruses</i> , <b>2004</b> , 20, 285-95	1.6	46
42	APOBEC-mediated editing of viral RNA. <i>Science</i> , <b>2004</b> , 305, 645	33.3	198
41	DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. <i>Nature Immunology</i> , <b>2003</b> , 4, 641-3	19.1	73

40	The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. <i>Nature Medicine</i> , <b>2003</b> , 9, 1404-7	50.5	788
39	DNA deamination mediates innate immunity to retroviral infection. <i>Cell</i> , <b>2003</b> , 113, 803-9	56.2	1134
38	Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. <i>Journal of Virology</i> , <b>2003</b> , 77, 5810-20	6.6	58
37	Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. <i>Nature</i> , <b>2002</b> , 418, 646-50	50.4	1852
36	A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. <i>Journal of Virology</i> , <b>2002</b> , 76, 10942-50	6.6	174
35	Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. <i>Journal of Virology</i> , <b>2002</b> , 76, 7874-82	6.6	100
34	Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. <i>Journal of Virology</i> , <b>2002</b> , 76, 12087-96	6.6	132
33	Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4. <i>Journal of Virology</i> , <b>2001</b> , 75, 3903-15	6.6	91
32	In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. <i>Journal of Virology</i> , <b>2001</b> , 75, 278-91	6.6	73
31	cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. <i>Journal of Virology</i> , <b>2001</b> , 75, 12028-38	6.6	158
30	Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging. <i>Journal of Virology</i> , <b>2001</b> , 75, 8348-52	6.6	19
29	Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). <i>Journal of Virology</i> , <b>2001</b> , 75, 10537-42	6.6	52
28	HIV-1 infection requires a functional integrase NLS. <i>Molecular Cell</i> , <b>2001</b> , 7, 1025-35	17.6	174
27	HIV-1 sequence variation: drift, shift, and attenuation. <i>Cell</i> , <b>2001</b> , 104, 469-72	56.2	157
26	Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. <i>Journal of Virology</i> , <b>2000</b> , 74, 4361-76	6.6	143
25	Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains. <i>Journal of Virology</i> , <b>2000</b> , 74, 693-701	6.6	45
24	Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. <i>Journal of Virology</i> , <b>2000</b> , 74, 10074-80	6.6	558
23	Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function. <i>Virology</i> , <b>1998</b> , 248, 182-7	3.6	35

22	Evidence for a newly discovered cellular anti-HIV-1 phenotype. <i>Nature Medicine</i> , <b>1998</b> , 4, 1397-400	50.5	225
21	The HIV-1 Rev protein. <i>Annual Review of Microbiology</i> , <b>1998</b> , 52, 491-532	17.5	590
20	HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. <i>Science</i> , <b>1998</b> , 280, 1880-3	34.3	326
19	Sequence requirements for Rev multimerization in vivo. <i>Virology</i> , <b>1994</b> , 202, 186-94	3.6	65
18	Secreted placental alkaline phosphatase as a eukaryotic reporter gene. <i>Methods in Enzymology</i> , <b>1992</b> , 216, 362-8	1.7	143
17	The HIV-1 Rev protein: prototype of a novel class of eukaryotic post-transcriptional regulators. <i>Trends in Biochemical Sciences</i> , <b>1991</b> , 16, 346-50	10.3	95
16	HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. <i>Cell</i> , <b>1991</b> , 65, 241-8	56.2	371
15	A highly conserved RNA folding region coincident with the Rev response element of primate immunodeficiency viruses. <i>Nucleic Acids Research</i> , <b>1990</b> , 18, 1613-23	20.1	83
14	HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. <i>Cell</i> , <b>1990</b> , 60, 675-83	56.2	405
13	Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function. <i>Cell</i> , <b>1989</b> , 58, 205-14	56.2	684
12	The production of hybrid Ty:IFN virus-like particles in yeast. <i>Nucleic Acids Research</i> , <b>1987</b> , 15, 7571-80	20.1	14
11	Expression strategies of the yeast retrotransposon Ty: a short sequence directs ribosomal frameshifting. <i>Nucleic Acids Research</i> , <b>1986</b> , 14, 7001-16	20.1	63
10	Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19		1
9	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: results from a pilot service		2
8	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England		1
7	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings		10
6	Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection		146
5	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 transmission identifies community social distancing as the dominant intervention reducing outbreaks		3

4	Indicators of past COVID-19 infection status: Findings from a large occupational cohort of staff and postgraduate research students from a UK university	1
3	Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines	27
2	Comparative performance of SARS CoV-2 lateral flow antigen tests demonstrates their utility for high sensitivity detection of infectious virus in clinical specimens	7
1	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms	1